Vertex Pharmaceuticals Inc (VRTX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$442.10
Buy
$443.00
$2.01 (+0.46%)
Prices updated at 19 May 2025, 22:00 EDT
| Prices minimum 15 mins delay
Prices in USD
Vertex Pharmaceuticals Inc is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases in specialty markets. Its products include SYMDEKO, ORKAMBI, and KALYDECO.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Most recent dividend payment
| - | |
| - | |
| - | |
| - | |
| - | |
| - |
Total dividend yield
Dividend history and forecast data table
| Year | Dividend per share | Dividend growth (%) |
|---|---|---|
| 2025 | - | - |
| 2024 | - | - |
| 2023 | - | - |
| 2022 | - | - |
| 2021 | - | - |
| 2020 | - | - |
| 2019 | - | - |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
Total dividend yield data table
Year | Dividend yield (%) | Buyback yield (%) |
|---|---|---|
| 2025 | - | 1.21 |
| 2024 | - | 1.27 |
| 2023 | - | 0.48 |
| 2022 | - | 0.73 |
| 2021 | - | 2.40 |
| 2020 | - | 1.02 |
| 2019 | - | 0.53 |
| 2018 | - | - |
| 2017 | - | - |
| 2016 | - | - |
Dividend per share
No data available
% of earnings paid to shareholders
No data available
Dividend per share data table
| Year | Dividend per share |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
% of earnings paid to shareholders data table
| Year | Payout ratio (%) |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
Latest Financial Report as of 16 May 2025
Dividend amount and dividend per share are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns.
